Hypothyroidism

Need a Buoy? Buoy Health Launches the Future of Personalized Care with a Digital Health Marketplace

Retrieved on: 
목요일, 6월 30, 2022
People, Insurance, Harvard Innovation Labs, Weight gain, Patient, Travel, COPD, Female, Triage, Digital, Awareness, Fatigue, Male, Health, JD, Solution, FIT, Cancer, LabCorp, Constipation, Hypothyroidism, Algorithm, Health insurance, Medicine, Google, Buoy, MD

BOSTON, June 30, 2022 /PRNewswire/ -- AI-powered health platform Buoy Health (Buoy) today announced the official launch of its healthcare marketplace. Currently, the marketplace includes more than three dozen care solutions that span comprehensive physical, mental, and specialized health needs. This new offering connects users with an ever-growing marketplace of digital health options. Buoy's two million-plus monthly users can access its platform and marketplace partners while paying out of pocket or utilizing their insurance provider when applicable for any care they might receive.

Key Points: 
  • Buoy Health Officially Launches Its Healthcare Marketplace Offering to Centralize and Streamline Digital Health Access; Match to Best Care Path
    BOSTON, June 30, 2022 /PRNewswire/ -- AI-powered health platform Buoy Health (Buoy) today announced the official launch of its healthcare marketplace.
  • "We believe the future of digital health hinges on the ability for any person, no matter their background or need, to receive personalized, effective care."
  • Buoy is a Boston-based digital health company that provides personalized clinical guidance the moment an individual has a health concern and matching to covered care options.
  • Buoy works with employers, health plans, and health solutions to simplify and streamline discovery and access to the right covered care options.

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Retrieved on: 
토요일, 6월 25, 2022
Cirrhosis, NASH, Patient, Liver, Research, Fatty liver disease, GLOBE, Hypothyroidism, Magnetic resonance imaging, Communication, ELF, Fibrosis, Webcast, Knowledge, GGT, FDA, ALT, Achievement, NAFLD, Population, Quarter, Disclosure, Liver disease, Therapy, CAP, MAST, SEC, Risk, Time, Abstract (summary), Forward-looking statement, European Association for the Study of the Liver, Judgement, THR, MRE, Investor, Elastography, Private Securities Litigation Reform Act, Nasdaq, Week, NASDAQ, Health, Annual report, Doctor's visit, Biopsy, 2021 Essex County Council election, Biomarker, EASL, U.S. Securities and Exchange Commission, Association, Compte rendu, AST, Clinical trial, Principal, University of Oxford, Safety, Accelerated approval (FDA), Program, Dietary supplement, Pharmaceutical industry, Medical imaging, Risk management, Madrigal, NAS

Similar to patients with non-cirrhotic NASH, liver volume was greatly elevated compared to normal at baseline.

Key Points: 
  • Similar to patients with non-cirrhotic NASH, liver volume was greatly elevated compared to normal at baseline.
  • MAESTRO-NASHis a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of resmetirom in patients with liver biopsy-confirmedNASHand was initiated inMarch 2019.
  • Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need.
  • Resmetirom is currently being evaluated in two Phase 3 clinical studies (MAESTRO-NASH and MAESTRO-NAFLD-1) designed to demonstrate multiple benefits in patients with NASH.

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Retrieved on: 
토요일, 6월 4, 2022
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MSD, CR, Hyperglycemia, Urinary bladder, AUA, Urine, Society, Hypothyroidism, AACR, Cystectomy, Toxicity, American Urological Association, BCG, ASCO, American Association for Cancer Research, Annual general meeting, H. Lee Moffitt Cancer Center & Research Institute, American Society of Clinical Oncology, Nocturia, American Association, Pembrolizumab, Patient, Merck Sharp & Dohme Federal Credit Union, Bladder cancer, Nivolumab, Twitter, MD, Population, Hematuria, Chills, Safety, Merck & Co., Pharmaceutical industry, Medical imaging, Vaccine, Fatigue, NMIBC, MIBC, Merck, Dysuria, Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology

CG Oncology, Inc. , a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, today announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • CG Oncology, Inc. , a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, today announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
  • As of the interim analysis, based on a data cutoff on May 13, 2022, 24 patients were evaluable for efficacy with a minimum of 3 months follow up.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.
  • At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Global $129+ Bn Cancer Biologics Market Research, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com

Retrieved on: 
수요일, 5월 18, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Lymphoma, Acute myeloid leukemia, Multiple myeloma, Physician, Hypothyroidism, Company, Conditional sentence, Breast cancer, Patient, Disability, Vaccine, Health, Novartis, Johnson & Johnson, Diarrhea, Hoffmann-La Roche, Time, Biotechnology, Bristol Myers Squibb, Amgen, Prostate cancer, GlaxoSmithKline, Hospital, Biomarker, Allergy, Ovarian cancer, Large-cell lung carcinoma, Hereditary diffuse gastric cancer, Colorectal cancer, Eli Lilly and Company, Distribution, AbbVie, Protein, Mouth, GI, Prevalence, Cancer, Growth, Application, Historic Market Place, Hildesheim, Hepatitis, NCBI, Dietary supplement, Medical imaging, Pfizer

The "Cancer biologics Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer biologics Global Market Report 2022: By Type, By Application, By Distribution" report has been added to ResearchAndMarkets.com's offering.
  • The cancer biologics market consists of sales of cancer biologics.
  • The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics.
  • Global Cancer biologics Forecast Market, 2021-2026F, 2031F, $ Billion

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Retrieved on: 
월요일, 5월 16, 2022
Biotechnology, Health, Oncology, Clinical Trials, MSD, American Association for Cancer Research, Hypothyroidism, Immunotherapy, Immunogenic cell death, Annual general meeting, Chills, Bladder cancer, American Urological Association, Urine, Hematuria, GM, Patient, Merck & Co., AACR, Session, Nocturia, Merck Sharp & Dohme Federal Credit Union, Pembrolizumab, Hyperglycemia, Antigen, BCG, AUA, Safety, GM-CSF, NMIBC, Rupture, American Association, Nivolumab, Urinary bladder, CR, Pharmaceutical industry, Dysuria, Merck, Fatigue

91% of patients evaluable for efficacy (n=20/22) have achieved complete response (CR) at the initial 3-month timepoint.

Key Points: 
  • 91% of patients evaluable for efficacy (n=20/22) have achieved complete response (CR) at the initial 3-month timepoint.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.
  • Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO (nivolumab), and additional indications in other solid tumors are being pursued with CG0070 in combination with other immune checkpoint inhibitors.
  • At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Retrieved on: 
수요일, 5월 11, 2022
Mental Health, Health, General Health, Pharmaceutical, Optical, Biotechnology, Lazarus, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Exophthalmos, Lists of World Heritage Sites, Instagram, Twitter, Nasdaq, Fibroblast, Autoimmunity, Courage, Red, Depression, Grave, Thyroid disease, Hypothyroidism, Patient, Mental Health Awareness Month, TED, Letter, Severe cognitive impairment, Family, Hyperthyroidism, Anxiety, Cell, Epidemiology, Television, Health, Conditional sentence, Quality of life, LinkedIn, Graves' ophthalmopathy, Disease, Friends, Science, Autoantibody, European Group, Diplopia, Inflammation, Walking, Strabismus, TED (conference), Paced Auditory Serial Addition Test, American, Risk, Multimedia, Pharmaceutical industry, Health insurance, Vaccine, Silviculture, Atlantic Ocean, Facebook, The New York Times

Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.

Key Points: 
  • Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.
  • My relationship with TED hasnt been easy, but because of what Ive been through, I take pride in everything Ive accomplished.
  • It is important to monitor eye symptoms and take weekly pictures to capture any changes in appearance.
  • Cockerham K, Stuertz N, Padnick-Silver L. Quality of Life Assessment of Chronic Thyroid Eye Disease (TED) Patients in the United States.

Global Endocrine Testing Market Analysis/Research Report 2022-2027: Tests to Measure Thyroid-Stimulating Hormone (TSH) are Expected to Influence Market Growth - ResearchAndMarkets.com

Retrieved on: 
목요일, 4월 28, 2022
Health, Biotechnology, First Nations in Ontario, Triiodothyronine, Androgen deficiency, FT4, Thyroid disease, COVID-19, Roche, University Medical Center Groningen, Thyroid, Department, Geriatrics, ATA, American Thyroid Association, FT3, Incidence, Patient, UN, Tobacco, Growth, Risk, Laboratory, Abbott Laboratories, TT3, Growth hormone, Woman, Smoking, Groningen, CAGR, United Nations, Technology, Serum, Research, University of Groningen, Nephrology, Hypothyroidism, TSH, Menopause, University, Hyperthyroidism, Government, Disease, Endocrine system, Man, Medical device, Vaccine, Pharmaceutical industry, Agriculture

Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Key Points: 
  • Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.
  • Since endocrine testing tools are in high demand, market players are more committed to developing new products.
  • The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.
  • As a result, the rise in TSH testing is expected to boost market growth for the global endocrine testing market.

EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody® in Switzerland

Retrieved on: 
화요일, 4월 26, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, MAA, ODD, Prednisone, Sleep, Osteoporosis, Adrenal insufficiency, Marketing, Adult, European Commission, Dexamethasone, Hypogonadism, Hypothyroidism, Adolescence, CAH, Congenital adrenal hyperplasia, Birth, Infertility, Degenerative disease, Death, Patient, Hydrocortisone, Birth defect, Puberty, Suffering, Medication package insert, Mortality, MHRA, Prednisolone, Marketing Authorisation Application, Product, Physician, Union, FDA, Male, Androgen, Risk, Interim, Therapy, Adrenal crisis, Pharmaceutical industry, Diurnal, Swissmedic

EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.

Key Points: 
  • EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody as treatment for congenital adrenal hyperplasia (CAH) in Switzerland.
  • Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Efmody in Switzerland.
  • The MAA submission to Swissmedic for Efmody will be based on the European regulatory dossier and published clinical trial data, with EffRx expecting potential market launch in Switzerland in 2024.
  • We are pleased to deepen our relationship with EffRx to include the distribution and marketing of Efmody in Switzerland.

 CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Retrieved on: 
수요일, 4월 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Immunogenic cell death, GM-CSF, Annual general meeting, Association, Population, Autoimmune thyroiditis, Hypothyroidism, Merck & Co., Immunotherapy, AES, Chills, Merck Sharp & Dohme Federal Credit Union, Nivolumab, Urine, Patient, GM, Session, Urinary bladder, Șaeș, Pembrolizumab, Nocturia, BCG, CR, University of California, Irvine Medical Center, Antigen, American Association for Cancer Research, Rupture, Safety, Bladder cancer, American Association, Hematuria, NMIBC, AACR, Medical imaging, Pharmaceutical industry, Vaccine, Merck, Dysuria, Fatigue

The interim Phase 2 results showed that the combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 18 patients.

Key Points: 
  • The interim Phase 2 results showed that the combination of CG0070 and pembrolizumab was well tolerated with encouraging early efficacy data in 18 patients.
  • These interim results continue to support CG0070s promise in patients with bladder cancer unresponsive to BCG, a difficult-to-treat patient population, said Arthur Kuan, Chief Executive Officer, CG Oncology.
  • As of the interim analysis, based on a data cutoff on April 7, 2022, 18 patients were evaluable for efficacy.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.

Online Pharmacy in Canada Helping Americans Without Insurance

Retrieved on: 
화요일, 3월 22, 2022
People, OR, Pharmacy, CDC, Multimedia, Plasma protein binding, Hypertension, Prescription, Medicare Part D, View, Industry, Diabetes, International, US, Hypothyroidism, Medicare, Insurance, Patient, Pharmaceutical industry, Health insurance, Online shopping, BC

VANCOUVER, BC, March 22, 2022 /PRNewswire/ -- According to the US CDC, 64% of Americans under 65 have private insurance. They will be grateful for the peace of mind that comes with knowing they won't have to pay any out-of-pocket prescription medication costs. People with chronic conditions such as diabetes, hypertension, hypothyroidism and other medical issues need to be able to fill their prescriptions on a regular basis. A lot of medications needed to treat diabetes, hypertension, hypothyroidism, and other conditions can be expensive. An online pharmacy intermediary such as SaveRxCanada.to may be able to provide the savings that people require.

Key Points: 
  • An online pharmacy intermediary such as SaveRxCanada.to may be able to provide the savings that people require.
  • People without private insurance will be more affected by high prescription drug costs in America than those with private insurance (64%).
  • There are many other factors, but Americans with OR and without insurance may be interested in knowing if they can get cheaper drugs and if ordering from an online pharmacy is the best option.
  • Americans without insurance should investigate the cost of ordering medication from Canada.